Cover Image
市場調查報告書

轉移性卵巢癌:全球臨床實驗檢討

Ovarian Cancer Global Clinical Trials Review, H1, 2016

出版商 GlobalData 商品編碼 299726
出版日期 內容資訊 英文 1725 Pages
訂單完成後即時交付
價格
Back to Top
轉移性卵巢癌:全球臨床實驗檢討 Ovarian Cancer Global Clinical Trials Review, H1, 2016
出版日期: 2016年05月19日 內容資訊: 英文 1725 Pages
簡介

本報告提供轉移性卵巢癌相關臨床研究最新趨勢相關分析,以疾病概要為首,提供地區及主要國家的臨床實驗狀況,Phase別·各進展狀況臨床實驗資料,被實驗者的募集情況,有潛力的贊助商,以及彙整各企業·研究機關臨床實驗簡介等資訊,為您概述為以下內容。

目錄

簡介

  • 轉移性卵巢癌
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數和平均實驗人數
    • 亞太地區的主要5個國家
    • 歐洲的主要5個國家
    • 北美的主要國家
    • 中東非洲的主要國家

在G7各國臨床實驗

在G7各國臨床實驗:Phase別

在G7各國臨床實驗:各進展狀況

在E7各國臨床實驗

在E7各國臨床實驗:Phase別

在E7各國臨床實驗:各進展狀況

Phase別臨床實驗

  • 進行中的臨床實驗:Phase別

各進展狀況臨床實驗

一定期間所採用的實驗對象

贊助商的種類別臨床實驗

有潛力的贊助商

  • 參加轉移性卵巢癌治療藥臨床實驗的前幾名企業

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • F. Hoffmann-La Roche Ltd.
    • MolMed S.p.A.
    • Isis Pharmaceuticals, Inc.
    • E. Merck KG
    • 第一三共
    • AbbVie Inc.
    • Eli Lilly and Company
    • Cell Therapeutics, Inc.
    • California Stem Cell, Inc.
    • Bristol-Myers Squibb Company
  • 有代表性的醫院·研究機關臨床實驗概要
    • National Cancer Institute
    • NCIC Clinical Trials Group
    • University of Washington
    • The University of Texas Health Science Center at San Antonio
    • Rutgers, The State University of New Jersey
    • European Organization for Research and Treatment of Cancer
    • Albert Einstein College of Medicine of Yeshiva University
    • Karolinska Institutet
    • Weill Cornell Medical College

5個有代表性的臨床實驗簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3404CTIDB

GlobalData's clinical trial report, "Ovarian Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Ovarian Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Ovarian Cancer Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Ovarian Cancer
      • May 02, 2016: Novogen Provides Update On Development Of Cantrixil
      • May 02, 2016: Celsion Announces Positive Data from the First Cohort of Patients in the OVATION Study
      • Apr 29, 2016: SELLAS Life Sciences Group Announces Initiation of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial in Combination with PD-1 Checkpoint Inhibitor for Patients with Ovarian Cancer
      • Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference
      • Apr 21, 2016: Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting
      • Apr 21, 2016: OncoMed Announces Clinical Data for ipafricept to be Presented at the 2016 ASCO Annual Meeting
      • Apr 21, 2016: TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
      • Apr 19, 2016: Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin and Doxil
      • Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer
      • Apr 19, 2016: MacroGenics Presents Data from ROR1 x CD3 DART Preclinical Program at AACR Annual Meeting 2016
      • Apr 19, 2016: New class of small molecule drug, SI-2, has potential for improving cancer treatment
      • Apr 18, 2016: DelMar's VAL-083 Demonstrates Promise in the Treatment of Non-Small Cell Lung Cancer and Ovarian Cancer
      • Apr 18, 2016: Morphotek Announces Publication of Phase 3 Results From MORAb-003-004 Trial in Platinum-Sensitive Ovarian Cancer Patients
      • Apr 17, 2016: Precision Biologics, a NantWorks Company, to Present Combination Immunotherapy of a Novel Neo-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016
      • Apr 14, 2016: Asana BioSciences, to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program at the American Association for Cancer Research Annual Meeting
      • Apr 12, 2016: Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer
      • Apr 07, 2016: TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
      • Apr 01, 2016: Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer
      • Apr 01, 2016: SELLAS Life Sciences to Present Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting and the 13th International Conference of the International Mesothelioma Interest Group (iMig)
      • Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
      • Mar 22, 2016: CytRx to Present New Data Using Its Proprietary LADR Technology at the 2016 American Association for Cancer Research Annual Meeting
      • Mar 21, 2016: Oncolytics Biotech Reports Data from Randomized Phase 2 Study of REOLYSIN in Ovarian Cancer
      • Mar 16, 2016: Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin and Doxil at the AACR Annual Meeting 2016
      • Mar 16, 2016: Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting
      • Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting
      • Mar 16, 2016: Verastem to present data supporting FAK inhibition at the 2016 American Academy of cancer research annual meeting
      • Mar 10, 2016: PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study
      • Mar 08, 2016: Innovative Approach to Ovarian Cancer Treatment Unveiled by Biomedical Scientists at the Lankenau Institute for Medical Research
      • Mar 04, 2016: Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology
      • Mar 02, 2016: Propanc Confirms PRP Response to Broad Range of Cancer Indications; Sets Date for Scientific Advice Meeting with UK Regulators
      • Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers
      • Feb 12, 2016: Celsion Highlights Recent Pipeline Developments for its GEN-1 Immunotherapy Program and Provides Business Update
      • Feb 10, 2016: Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Ovarian Cancer Therapeutics, Global, Clinical Trials by Region, 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Ovarian Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top